<DOC>
	<DOCNO>NCT03061838</DOCNO>
	<brief_summary>This multicenter , double-blind , randomize clinical study safety , tolerability , pharmacokinetics pharmacodynamics biosimilar drug Ritumax® compare original drug MabThera® patient rheumatoid arthritis , receive stable dos Methotrexate . At Week -2 , sign Patient Information Sheet Informed Consent Form , patient rheumatoid arthritis receive stable dos Methotrexate ( 10-25 mg per week orally parenterally ) pas screening procedure . Patients meet inclusion/exclusion criterion invite investigational site Visit 2 ( Week 0 ) randomize one two treatment arm : - Ritumax® 1000 mg х 2 intravenous infusion - MabThera® 1000 mg х 2 intravenous infusion After assign treatment arm patient receive course study treatment , include two i/v infusion 14-day interval : Week 0 Week 2 . After , patient follow next 22 week . Safety , pharmacokinetic pharmacodynamic parameter monitor visit .</brief_summary>
	<brief_title>Safety , Tolerability , PK PD Biosimilar Drug Ritumax® Compared Original Drug MabThera®</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Signed Patient Information Sheet Informed Consent Form participate study . 2 . Men woman age 18 year old . 3 . Patient diagnose rheumatoid arthritis least 6month duration , determine accord classification criterion American College Rheumatology ( ACR ) European League Against Rheumatism ( EULAR ) ( ACREULAR 2010 ) American College Rheumatology ( ACR1987 ) ( case diagnosis rheumatoid arthritis determine till 2010 ) . 4 . Active phase disease confirm due combination follow parameter : DAS28 &gt; 3,2 5 ( 28 ) tender 5 ( 28 ) swollen joint CRP level ≥1,5 mg/dL and/or ESR &gt; 28 mm/h positive test rheumatoid factor and/or CCP antibodies 5 . Patients negative response intolerability DMARD therapy . 6 . Current outpatient therapy rheumatoid arthritis : continuous therapy Methotrexate least 12 week prior screen stable dos Methotrexate ( 1025 mg per week ) within 4 week prior screen currently corticosteroid therapy , dose stable within last 4 week prior screen less 10 mg Prednisolone equivalent currently NSAID therapy , dose stable within last 4 week prior screen The patient deem ineligible study meeting follow criterion : 1 . Other inflammatory arthropathy apart rheumatoid arthritis ( e.g . gout , reactive arthritis , psoriatic arthritis , seronegative spondyloarthropathy , Lyme desease ) system autoimmune disease ( e.g . systemic lupus erythematosus , inflammatory bowel disease , pneumosclerosis Felly 's syndrome , sclerodermia , inflammatory myopathy , mixed collagenosis cross syndrome ) . Patients secondary Sjorgen 's syndrome secondary limit cutaneous vasculitis rheumatoid arthritis background may participate study . 2 . Chronic heart failure Class III IV New York Heart Association ( NYHA ) classification clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation ) . 3 . Serious chronic pulmonary disease ( COPD , bronchial asthma ) ; functional dyspnea severity level III high ( due Medical Science Research Council scale dyspnea ) . 4 . Signs significant uncontrolled concomitant disease , e.g . renal , hepatic , gastrointestinal , endocrine system nervous system disorder , , accord Investigator 's opinion , could prevent patient 's participation study . 5 . Any surgical procedure , include bone joint surgery , synovectomy ( include arthrodesis endoprosthesis replacement ) , perform within 12 week prior screen plan perform within 24 week ( except small surgical procedure , require local anesthesia anesthesia ) . 6 . Infectious disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>